Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial

NCT05788601 is registered in ClinicalTrials.gov with University Hospital, Gentofte, Copenhagen as lead sponsor.

NCT NCT05788601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05788601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial
Lead sponsor
University Hospital, Gentofte, Copenhagen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 27, 2023
Completion date
August 15, 2025
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammation, obesity